Lamotrigine is under clinical development by Azurity Pharmaceuticals and currently in Pre-Registration for Lennox-Gastaut Syndrome. According to GlobalData, Pre-Registration drugs for Lennox-Gastaut Syndrome have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Lamotrigine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lamotrigine overview

Lamotrigine (AUC-025, ET-105) is under development for the treatment of partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome. It is a liquid formulation administered through oral route. It acts by targeting voltage-sensitive sodium channels.

Azurity Pharmaceuticals overview

Azurity Pharmaceuticals, a subsidiary of NovaQuest Capital Management LLC, is a pharmaceutical company that develops and distributes pharmacy kits. The company offers products such as oral suspensions, suppositories, oral solutions, and topical. Its oral solutions and oral suspensions include mouthwashes, anti-microbial and PPIs; and topicals comprise hydrocortisone and testosterone; and suppositories include progesterone VGS. Azurity Pharmaceuticals also provides facilities for distribution, warehousing, and manufacturing operations and management. The company serves hospital and long term care pharmacies, pharmacy chains, and independent pharmacies. It provides prescription compounding kits for physicians, patients, pharmacists, and managed care providers. Azurity Pharmaceuticals is headquartered in Woburn, Massachusetts, the US.

For a complete picture of Lamotrigine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.